| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $41.5M | -13.4% |
| SG&A Expense | $15.7M | -20.2% |
| Operating Income | -$59.7M | +11.7% |
| Net Income | -$55.7M | +11.3% |
| EPS (Basic) | -$1.99 | +11.6% |
| EPS (Diluted) | -$1.99 | +11.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $27.7M | +111.9% |
| Current Assets | $71.8M | -36.3% |
| Total Assets | $80.9M | -36.8% |
| Current Liabilities | $9.6M | +39.1% |
| Total Liabilities | $15.4M | +13.0% |
| Stockholders' Equity | $65.5M | -42.8% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$40.8M | +23.0% |
| Capital Expenditures | $474K | -42.2% |
| Investing Cash Flow | $55.3M | +40.8% |
| Financing Cash Flow | $144K | -6.5% |
| Free Cash Flow | -$41.3M | +23.3% |